Anebulo Pharmaceuticals, INC 10-Q quarterly reports

Anebulo Pharmaceuticals reports reduced net loss and a strategic shift to pediatric cannabis toxicity treatment, while initiating a going-private transaction.

Anebulo Pharmaceuticals reports a reduced net loss for Q1 2026, pivots its lead drug development to pediatric cannabis toxicity, and is actively reviewing strategic alternatives including a proposed going-private transaction.

Anebulo Pharmaceuticals focuses on developing intravenous selonabant for pediatric cannabis-induced toxicity while reporting financial results for the quarter ended March 31, 2025.

Anebulo Pharmaceuticals focuses on developing intravenous selonabant for pediatric cannabis toxicity while reporting a net loss of $4.66 million for the six months ended December 31, 2024.

Anebulo Pharmaceuticals reported a net loss of $2.2 million for the quarter ended September 30, 2024, and is prioritizing the development of an intravenous formulation of selonabant for pediatric cannabis toxicity.

Anebulo Pharmaceuticals reported its Q3 2024 financial results, highlighting a net loss and a strategic shift to prioritize an intravenous treatment for pediatric cannabis poisoning.

Anebulo Pharmaceuticals reported a net loss of $5.2 million for the six months ended December 31, 2023, while advancing its lead drug candidate, selonabant.